trial · primary record
Daratumumab
Amyloidosis
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 151 |
| Primary completion | 2026-11-12 |
| Primary endpoint | Number of Participants with Cardiac Events of Any Toxicity Grade |
| Registry ID | NCT05250973 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:48.770Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05250973
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Daratumumab · approval
- Daratumumab · compound